⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL294821 | 0.81 | — | — | |
| SCHEMBL269699 | 0.77 | ADH1A (0.40) | — | |
| SCHEMBL1998313 | 0.75 | MAPT (0.33) | — | |
| SCHEMBL18556781 | 0.75 | — | — | |
| SCHEMBL270274 | 0.73 | ADH1C (0.35) | — | |
| SCHEMBL1413067 | 0.71 | — | — | |
| SCHEMBL22142555 | 0.71 | ALDH1A1 (0.35) | — | |
| SCHEMBL22142651 | 0.71 | — | — | |
| SCHEMBL270858 | 0.70 | — | — | |
| SCHEMBL15803006 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9714560-B2 | Protected scale inhibitors and methods relating thereto | HALLIBURTON ENERGY SERVICES, INC. (US) | 2017-07-25 | — | — | US | claimed |
| US-20140038181-A1 | CHEMICALLY SUBSTITUTED THERMOSENSITIVE PROBES AND COFACTORS FOR HOT START LIGATION | TRILINK BIOTECHNOLOGIES, INC. | 2014-02-06 | — | — | US | claimed |
| US-8361753-B2 | Phosphotriester-modified oligonucleotide primers for nucleic acid amplification | TRILINK BIOTECHNOLOGIES, INC. (US) | 2013-01-29 | — | — | US | claimed |
| US-20120214817-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | MARYANOFF BRUCE E (US) | 2012-08-23 | — | — | US | claimed |
| WO-2012094343-A1 | CHEMICALLY SUBSTITUTED THERMOSENSITIVE PROBES AND COFACTORS FOR HOT START LIGATION | TRILINK BIOTECHNOLOGIES (US) | 2012-07-12 | — | — | WO | claimed |
| US-8193191-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-06-05 | — | — | US | claimed |
| EP-1993554-B1 | UROTENSIN II RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-23 | — | — | EP | claimed |
| US-20110136824-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | MARYANOFF BRUCE E | 2011-06-09 | — | — | US | claimed |
| US-7915260-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-03-29 | — | — | US | claimed |
| EP-2032714-B1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDE PRIMERS FOR NUCLEIC ACID AMPLIFICATION | TRILINK BIOTECHNOLOGIES (US) | 2011-03-16 | — | — | EP | claimed |
| EP-2032714-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDE PRIMERS FOR NUCLEIC ACID AMPLIFICATION | TriLink BioTechnologies (US) | 2009-03-11 | — | — | EP | claimed |
| EP-1993554-A2 | UROTENSIN II RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2008-11-26 | — | — | EP | claimed |
| WO-2007139723-A1 | CHEMICALLYMODIFIED OLIGONUCLEOTIDE PRIMERS FOR NUCLEIC ACID AMPLIFICATION | TRILINK BIOTECHNOLOGIES (US) | 2007-12-06 | — | — | WO | claimed |
| US-20070281308-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDE PRIMERS FOR NUCLEIC ACID AMPLIFICATION | TRILINK BIOTECHNOLOGIES, LLC | 2007-12-06 | — | — | US | claimed |
| US-20070191391-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | US | claimed |
| WO-2007081995-A2 | UROTENSIN II RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-19 | — | — | WO | claimed |
| CN-118355117-A | Oligonucleotide compositions and methods thereof | 波涛生命科学有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20240229026-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES LTD. (SG) | 2024-07-11 | — | — | US | disclosed |
| US-20050227254-A1 | Quencher compositions comprising anthraquinone moieties | QIAGEN GMBH (DE) | 2005-10-13 | — | — | US | disclosed |
| EP-1538154-A1 | Quencher composition comprising anthraquinone moieties | Exiqon A/S (DK) | 2005-06-08 | — | — | EP | disclosed |